Recently, DOJ announced  that pharmaceutical giant Pfizer, on behalf of its subsidiary, Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”), has agreed to pay nearly $60 million to resolve allegations that Biohaven knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to health care providers (“HCPs”) to induce prescriptions of Biohaven’s migraine drug Nurtec ODT before Pfizer acquired the company. The set

New revenue opportunities have opened up for radiology groups with CMS’ extension of flexibilities for the virtual supervision of radiology studies performed with contrast media. The extension allows facilities to provide Level 2 diagnostic tests, including CT and MRI scans, with a remotely located supervising provider through (at least) December 31, 2025. Before the COVID-19 epidemic in 2020, CT and MRI with contrast procedures had to be supervised by onsite physicians who w

The 2025 BFMV Call Coverage survey is currently open for data collection . Each spring, our survey reaches out directly to physicians for the most relevant call coverage information available. If you are a physician or practice administrator who would like your data to be included in this study, please submit information regarding your unrestricted call coverage arrangement here . Completing the survey takes less than 5 minutes and contributors receive complementary 1-year su

Looking ahead in 2025, the healthcare industry is set to experience a year filled with dynamic opportunities, particularly in mergers and...